• Japanese
  • Korean
  • Chinese
Cover Image

Phenotypic Drug Discovery Trends 2013

This market report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on phenotypic drug discovery (PDD) carried out in March 2013. The survey was initiated by HTStec as part of its tracking of this emerging life science marketplace.

The survey looked at the following aspects of PDD, as practiced today (2013) and in a few cases as predicted for the future (2015):

  • Current level of deployment (actual use); what features most highly the understanding of PDD
  • Importance of features in the definition/understanding of a phenotypic screening assay
  • Different assay types that fit within the definition/understanding of a phenotypic screening assay
  • Key diseases/therapeutic area(s) deploying phenotypic screening assays
  • Main motivators for wanting to adopt PDD
  • Key challenges of doing PDD
  • Obstacles which would most limit the adoption of phenotypic screening assays today
  • Number of FTE devoted in house to PPD
  • The number of primary phenotypic screens and data points per screen
  • The average cost per well of phenotypic screening assays
  • (Much more included in the full report)

Key Points Discussed in the Report:

  • Target deconvolution was rated the main obstacle limiting adoption of phenotypic screening assays.
  • The median cost of a phenotypic screening assay undertaken in 2013 was $0.5-$0.75 per well.
  • Human primary cells were ranked the cell type most relevant for phenotypic screening studies.
  • The median success rate for phenotypic primary screening in 2013 was 40%.
(The Contents on this Website is a Condensed Version of the Original Report. To View the Complete Version, Please Request a Sample.)

Table of Contents

  • Executive Summary
  • Table of Contents
  • Survey Methodology
  • Organisation & Response of Survey Participants
  • Respondent's Company or Organisational Origin
  • Respondent's Geographic Origin
  • Respondent's Main Group Activity
  • Respondent's Job Role
  • Current Use of PDD
  • Understanding of PDD and how it Differs From Target-Based Discovery
  • Most Important Features in Respondent's Understanding of PDD
  • Respondents Definition/Understanding of a Phenotypic Screening Assay
  • Importance of Features in Respondent's Definition of a Phenotypic Screening Assay
  • Assay Types That Fit Within the Definition of Phenotypic Screening Assays
  • Disease/Therapeutic Areas Targeting/Using Phenotypic Screening Assays
  • Main Motivators for Wanting to Adopt PDD
  • Summary of Survey Findings (1)
  • Key Challenges of Doing PDD
  • Biggest Limitations (Obstacles) in Using Phenotypic Screening Assays Today
  • Potential Obstacles Limiting Adoption of Phenotypic Screening Assays
  • No. of FTE's Devoted In House to PDD
  • No. of PDD Projects or Programs Supported
  • No. Phenotypic Primary Screens Run Per Year
  • No. of Wells Per Phenotypic Primary Screen
  • Average Cost Per Well of Phenotypic Screening Assays Undertaken
  • Cell Types Most Suited for Phenotypic Screening Studies
  • Respondent's Expectations for Phenotypic Screening
  • Average % Success Rate for Phenotypic Primary Screens
  • Where Phenotypic Assays are Most Suited to be Used
  • Target Deconvolution Approaches Used or Preferred for PDD
  • Level of Agreement on Statements About PDD
  • What are the Prerequisites for Starting PDD?
  • Summary of Survey Findings (2)
  • Is There a Critical Path for PDD?
  • Respondent's Who Have Made Changes in Their Organisation as a Result of Pursuing PDD
  • Types of Compound Collection That Should be Screened in PDD
  • Does PDD Require New Compound Libraries?
  • Annual Reagent & Consumables Budget for Phenotypic Assays
  • Breakdown of Phenotypic Assay Reagent & Consumables Budget
  • Phenotypic Assay Reagents & Consumables Market Estimate
  • Phenotypic Assay Reagents & Consumables Market Segmentation
  • Breakdown of Phenotypic Assay Reagents & Consumables Market
  • Assay Technologies & Instrument Platforms Preferentially Used or Expect to Make Greatest Use in the Future for PDD
  • Key Vendors of PDD Assay Reagents (1)
  • Key Vendors of PDD Assay Reagents (2)
  • Key Vendors of PDD Instrument Platforms (1)
  • Preferred Key Vendors of PDD Instrument Platforms (2)
  • Biggest Unmet Needs in PDD and What New Tools are Required to Drive the Investigation of Phenotypic Screening Assays
  • Summary of Survey Findings (3)
Show More
  • Int'l: +1-860-674-8796
  • TollFree(US): +1-866-353-3335
  • Europe: +32-2-535-7543
  • Asia: +65-6223-2436
Back to Top